Olaparib
Interviews and expert commentary tagged “Olaparib” — the latest oncology research and clinical practice from the Audio Journal of Oncology.
Audio Journal of Oncology
Christian Singer MD: Neoadjuvant Olaparib Combination Beats Standard of Care in Patients with Homologous Recombination Deficient BRCA 1/2-Positive Triple-Negative Breast Cancer
Homologous Repair Deficient Triple Negative Breast Cancer Positive for BRCA1/2 Mutations Better with Neoadjuvant Olaparib + Carboplatin
5 August 2025
10:32
Audio Journal of Oncology
First Line PARP Inhibition For Ovarian Cancer Assessed
MUNICH—The role of poly ADP ribose polymerase (PARP) inhibitors for treating newly diagnosed advanced ovarian cancer was under review at the 2018 annual congress of the European Society for Medical On
2 November 2018
7 Minutes
Audio Journal of Oncology
BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib
BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib MUNICH—An “unprecedented improvement” in progression free survival (PFS) was observed in the randomized controlled
1 November 2018
8 mins